MCR-1 and OXA-48 In Vivo Acquisition in KPC-Producing Escherichia coli after Colistin Treatment | Zendy

Racha Beyrouthy | Zendy; Frédéric Robin | Zendy; Aude Lessene | Zendy; Igor Lacombat | Zendy; Laurent Dortet | Zendy; Thierry Naas | Zendy; Valérie Pontiès | Zendy; Richard Bonnet | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

MCR-1 and OXA-48 In Vivo Acquisition in KPC-Producing Escherichia coli after Colistin Treatment

Author(s) -

Racha Beyrouthy,

Frédéric Robin,

Aude Lessene,

Igor Lacombat,

Laurent Dortet,

Thierry Naas,

Valérie Pontiès,

Richard Bonnet

Publication year - 2017

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.02540-16

Subject(s) - mcr 1 , plasmid , colistin , escherichia coli , klebsiella pneumoniae , enterobacteriaceae , microbiology and biotechnology , biology , bacteria , carbapenem , strain (injury) , enterobacteriaceae infections , gene , antimicrobial , genetics , antibiotics , anatomy

The spread of mcr-1 -encoding plasmids into carbapenem-resistant Enterobacteriaceae raises concerns about the emergence of untreatable bacteria. We report the acquisition of mcr-1 in a carbapenem-resistant Escherichia coli strain after a 3-week course of colistin in a patient repatriated to France from Portugal. Whole-genome sequencing revealed that the Klebsiella pneumoniae carbapenemase-producing E. coli strain acquired two plasmids, an IncL OXA-48-encoding plasmid and an IncX4 mcr-1 -encoding plasmid. This is the first report of mcr-1 in carbapenemase-encoding bacteria in France.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research